14th September 2018
- 0 comments
A novel anti-bacterial agent which has been developed in Scotland by MGB Biopharma for the treatment of Clostridium difficile infections, is to enter Phase II clinical trials following a newly-completed £1.3m fund raise from existing and new investors, supplementing a £2.7m grant awarded earlier this year by Innovate UK.
...In order to read the full story we need you to be registered with us, please click the links below to login or register.